BHCFX Mutual Fund

BHCFX Mutual Fund

NAV$23.06
See how much of BHCFX you already own
Just $25 once·$99/mo·Download sample
X-ray my portfolio free

Fund Essentials - as of Mar 31, 2026

Net Assets
-
Expense Ratio
1.10%
Dividend Yield (Current)
-
Holdings
41
Inception Date
Apr 30, 2018
Fund Family
Baron Funds
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Unspecified

Performance

YTD+3.68%
1 Year+24.67%
3 Year+5.24%
5 Year+0.70%

Asset Allocation

Stocks: 100.00%
See how much of BHCFX you already own
Your funds unpacked, overlap, fees and score, free on screen. The full report is $25, once. Download sample.
X-ray my portfolio free

Top Holdings

View All →
TickerNameWeight
LLYEli Lilly & Co.9.95%
AZN:LNAstraZeneca PLC5.09%
JNJJohnson & Johnson - Common4.58%
TMOThermo Fisherscientific Inc.4.25%
MTDMettler-Toledo International Inc.3.99%
Top 10 Concentration: 43.86%Report Date: Mar 31, 2026
Download all 41 holdings for BHCFX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Frequency
Unspecified
Latest Distribution
$0.22
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO

BHCFX Mutual Fund Overview

BHCFX Mutual Fund (Baron Health Care Fund Retail Class) is managed by Baron Funds. BHCFX expense ratio is 1.10%, holding 41 positions across sectors including Health Care, Real Estate. Inception date: 2018-04-30.

BHCFX performance shows a YTD return of 3.68%. The 1-year return is 24.67% and the 5-year return is 0.70%.

BHCFX top holdings include Eli Lilly & Co. (9.9%), AstraZeneca PLC (5.1%), Johnson & Johnson - Common (4.6%), Thermo Fisherscientific Inc. (4.3%), Mettler-Toledo International Inc. (4.0%). Go to all BHCFX holdings, BHCFX sectors, or BHCFX dividends.

BHCFX can be compared against other funds. Use BHCFX overlap to find shared positions, or BHCFX vs another fund for a side-by-side view. BHCFX alternatives are available via the screener, along with tax-loss harvesting opportunities.